Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
167 participants
INTERVENTIONAL
2014-01-27
2021-10-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Anti-telomerase T CD4 Immunity in Melanoma
NCT02838433
Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1
NCT02840058
Identification of Innovative Biomarkers Related to the Immune System or Tumor Microenvironment to Promote the Efficacy of Immunotherapies
NCT06626269
COVID-19-Study of Immune Responses Following Vaccination Against SARS-CoV-2
NCT04836793
Study of Polyfunctionality of Anti-tumor T Lymphocytes in Cancerology: Potential Biomarker for Emerging Immunotherapies
NCT02880046
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
glioma
1 additional blood sample for patients with glioma and without treatment
additional blood sample
breast cancer
2 additional blood samples for patients with localized brest cancer, metastatic breast cancer in 1st line of treatment and breast cancer in second line of treatment.
additional blood sample
breast cancer HER2+
1 additional blood sample for patients with metastatic breast cancer with HER2 surexpression
additional blood sample
Breast Cancer HER 2+ or HER2 triple -
1 additional blood sample for patients with breast cancer HER2 + or HER2 triple negative treated by neo adjuvant
additional blood sample
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
additional blood sample
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* breast cancer or glioma
* Arm glioma: patients without anti-tumoral treatment
* Arm breast cancer: inclusion before treatment
* Arm breast cancer HER2: patients with current therapy
Exclusion Criteria
* vulnerable People according to the law (minors, adults under protection, private persons of freedom ...)
* Unaffiliated People to the Social Security
* People being for the period of exclusion from another study
* Life expectancy estimated unless 3 months.
* For patients in Arm glioma: patients having already begun a systematic treatment.
* For patients with a breast cancer: patient already under current therapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Besancon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Régional Universitaire
Besançon, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P/2013/188
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.